Thalassemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Thalassemia Clinical Trials Market Report Overview
The Thalassemia clinical trial market research report provides an overview of the Thalassemia clinical trials scenario. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Thalassemia Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Thalassemia clinical trials market are North America, Asia-Pacific, Middle East & Africa, Europe, and South & Central America. North America dominates the market with around 30% of the clinical trials conducted on thalassemia, as of February 2023, followed by Asia-pacific, and Middle East & Africa.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada and Japan) countries, Italy has the highest proportion of Thalassemia to Hematological Disorders clinical trials as of February 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Indonesia has the highest proportion of Thalassemia to Hematological Disorders clinical trials as of February 2023.
Thalassemia Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the Thalassemia clinical trials market, download a free report sample
Thalassemia Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Thalassemia clinical trials market are institution, company, and the government. Out of them, more than 60% of trials have been sponsored by institution, followed by company.
Thalassemia Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the Thalassemia clinical trials market, download a free report sample
Thalassemia Clinical Trials Market - Competitive Landscape
Some of the leading sponsors in the Thalassemia clinical trials market are Novartis AG, Bristol-Myers Squibb Co, Agios Pharmaceuticals Inc, bluebird bio Inc, Merck & Co Inc, Thermo Fisher Scientific Inc, Takeda Pharmaceutical Co Ltd, Sanofi, Pfizer Inc, and CRISPR Therapeutics AG. Novartis AG has conducted the highest number of Thalassemia clinical trials and is followed by Bristol-Myers Squibb Co and Agios Pharmaceuticals Inc respectively.
Thalassemia Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading sponsors in the Thalassemia clinical trials market, download a free report sample
Thalassemia Clinical Trials Market Report Overview
Key Regions | Europe, North America, Asia-Pacific, the Middle East & Africa, and South & Central America |
Key Countries (G7) | United States, United Kingdom, Germany, France, Italy, Canada, and Japan |
Key Countries (E7) | Brazil, Russia, India, China, Mexico, Turkey, and Indonesia |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Novartis AG, Bristol-Myers Squibb Co, Agios Pharmaceuticals Inc, bluebird bio Inc, Merck & Co Inc, Thermo Fisher Scientific Inc, Takeda Pharmaceutical Co Ltd, Sanofi, Pfizer Inc, and CRISPR Therapeutics AG |
Segments Covered in the Report
Thalassemia Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
Thalassemia Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end-point status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with reasons for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies about investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Bristol-Myers Squibb Co
Agios Pharmaceuticals Inc
bluebird bio Inc
Merck & Co Inc
Thermo Fisher Scientific Inc
Sanofi
Takeda Pharmaceutical Co Ltd
CRISPR Therapeutics AG
Pfizer Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which was the leading region in the Thalassemia clinical trials market?
North America dominates the Thalassemia clinical trials market as of February 2023.
-
Which was the leading country in the G7 Thalassemia clinical trials market?
Italy has the highest proportion of Thalassemia to Hematological Disorders clinical trials as of February 2023.
-
Which was the leading country in the E7 Thalassemia clinical trials market?
Indonesia has the highest proportion of Thalassemia to Hematological Disorders clinical trials as of February 2023.
-
What are the key sponsor types in the Thalassemia clinical trials market?
The key sponsor types in the Thalassemia clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the Thalassemia clinical trials market?
Some of the leading sponsors in the Thalassemia clinical trials market are Novartis AG, Bristol-Myers Squibb Co, Agios Pharmaceuticals Inc, bluebird bio Inc, Merck & Co Inc, Thermo Fisher Scientific Inc, Takeda Pharmaceutical Co Ltd, Sanofi, Pfizer Inc, and CRISPR Therapeutics AG.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.